The advent of PARP inhibition continues to change the treatment paradigm for ovarian cancer, with emerging data, guideline updates, new global approvals, and expanded indications occurring frequently with more still expected. With this growing understanding of the homologous recombination repair pathway and its role in ovarian cancer, the potential applications of PARP inhibitors continue to expand. This activity will improve the knowledge and competency of pharmacists, nurses, and other healthcare professionals about the role of PARP inhibitors in ovarian cancer and the management of adverse events associated with PARP inhibitors.
The target audience for this activity is pharmacists, including specialty pharmacists and other pharmacists who care for patients with ovarian cancer. In addition, the target audience includes nurses across the continuum, pharmacy directors, chief pharmacy officers, health plan administrators, health-systems, group purchasing organizations, and other stakeholders in specialty pharmacy.
After completing the activity, participants should be able to:
- Describe the role of PARP inhibitors in the setting of frontline and recurrent ovarian cancer.
- Analyze recent clinical data on PARP inhibition as single-agent or in combination with chemotherapy, targeted therapy, and immunotherapy.
- Implement recommended strategies to monitor adherence and manage adverse events associated with PARP inhibitors.
Colleen Bohnenkamp, PharmD, BCOP, BCPS
Oncology Clinical Pharmacist
The University of Kansas Health System, Bloch Cancer Center
Kansas City, KS
Dane Fritzsche, PharmD, BCOP
Clinical Oncology Pharmacist
Pharmacy, Seattle Cancer Care Alliance/UW Medicine
Department of Pharmacy, University of Washington
Release Date: November 22, 2021
Expiration Date: November 22, 2022
ACPE Credit Designation (Pharmacist CE)
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-254-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Colleen Bohnenkamp, PharmD, BCOP, BCPS, has disclosed that she has no conflicts of interest to report.
Dane Fritzsche, PharmD, BCOP, has disclosed that he has no conflicts of interest to report.
The planners/managers reported the following relationships:
Gordon Kelley; Timothy A. Quill, PhD; Jason Everly, PharmD, BCOP, CHCP; Julie Skowronski, MSN, NP; and Jerfiz Constanzo, PhD, MBA, have no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by educational grants from GlaxoSmithKline and AbbVie, Inc.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.